Why the study?
Effective treatment of hypertension often requires multiple drug combinations to meet target guidelines, leading to the use of multidrug single-pill combinations to facilitate cost and compliance.
The nebivolol/valsartan single-pill combination provides an effective multidrug approach to meet target blood pressure guidelines.
May support nebivolol/valsartan SPC evaluation in hypertension; leaves open need for long-term outcome data.
-adrenoreceptor antagonist that is approved for treatment of hypertension in the USA. Effective treatment of hypertension is becoming an increasingly difficult process that often requires multiple drug combinations to meet target guidelines. This has resulted in the increasing introduction of multidrug single-pill combinations (SPCs) to facilitate cost and compliance issues. Some of the SPCs have added valsartan (V), an angiotensin receptor blocker, which is an increasingly advocated antihypertensive class. Pharmacological profiles of N and V, alone and combined, are well characterized. In 2007, the SPC of N and V, 5 and 80 mg, respectively, was approved by the US FDA for treatment of hypertension. This paper will summarize and update key issues in pharmacology, clinical use and benefit.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: